The pathophysiology of neurodegenerative diseases is poorly understood and there are few therapeutic options. Neurodegenerative diseases are characterized by progressive neuronal dysfunction and loss, and chronic glial activation 1 . Whether microglial activation, which is generally viewed as a secondary process, is harmful or protective in neurodegeneration remains unclear 1-8 . Late-onset neurodegenerative disease observed in patients with histiocytoses 9-12 , which are clonal myeloid diseases associated with somatic mutations in the RAS-MEK-ERK pathway such as BRAF(V600E) 13-17 , suggests a possible role of somatic mutations in myeloid cells in neurodegeneration. Yet the expression of BRAF(V600E) in the haematopoietic stem cell lineage causes leukaemic and tumoural diseases but not neurodegenerative disease 18, 19 . Microglia belong to a lineage of adult tissue-resident myeloid cells that develop during organogenesis from yolk-sac erythro-myeloid progenitors (EMPs) distinct from haematopoietic stem cells 20-23 . We therefore hypothesized that a somatic BRAF(V600E) mutation in the EMP lineage may cause neurodegeneration. Here we show that mosaic expression of BRAF(V600E) in mouse EMPs results in clonal expansion of tissueresident macrophages and a severe late-onset neurodegenerative disorder. This is associated with accumulation of ERK-activated amoeboid microglia in mice, and is also observed in human patients with histiocytoses. In the mouse model, neurobehavioural signs, astrogliosis, deposition of amyloid precursor protein, synaptic loss and neuronal death were driven by ERK-activated microglia and were preventable by BRAF inhibition. These results identify the fetal precursors of tissue-resident macrophages as a potential cellof-origin for histiocytoses and demonstrate that a somatic mutation in the EMP lineage in mice can drive late-onset neurodegeneration. Moreover, these data identify activation of the MAP kinase pathway in microglia as a cause of neurodegeneration and this offers opportunities for therapeutic intervention aimed at the prevention of neuronal death in neurodegenerative diseases.
pulse-labelled Braf LSL-V600E Csf1r MeriCreMer (Braf VE ) mice (Fig. 1f ). The proportion of F4/80 + YFP + macrophages was increased in tissues from Braf VE mice in comparison to control littermates (Fig. 1e) . In situ Ki-67, phosphorylated histone H3 and cleaved caspase-3 staining of brain microglia indicated an increased proliferative index and decreased apoptosis in BRAF(V600E) YFP + microglia ( Fig. 1g and Extended Data Fig. 1f ). RNA-seq analysis of Kupffer cells and microglia from Braf VE mice and control littermates identified a mitotic gene expression signature, as well as expression of ERK target genes, inflammatory cytokines and lectins ( Fig. 1h , i, Extended Data Fig. 1g and Supplementary Tables 1, 2) . Nevertheless, histological and flow cytometry analysis of liver, brain, lung, kidney, bone marrow and spleen from young Braf VE mice revealed no overt abnormalities, and, in particular, no tumoural or leukaemic phenotypes (Extended Data Fig. 1h ). This is in contrast to results obtained when targeting Braf V600E alleles in HSCs using Vav1 cre ; Braf LSL-V600E mice 19 and Csf1r iCre ;Braf LSL-V600E mice or in more mature HSC-derived myeloid precursors as achieved in CD11c cre ;Braf (also known as Itgax cre ;Braf LSL-V600E ) mice (ref. 18 and Extended Data Figs 2, 3) . In each of these models, expression of Braf V600E in HSCs or HSC-derived cells resulted in a highly penetrant (100%) leukaemic or tumoural histiocytic phenotype in the bone marrow, spleen and lung. Together, these data show that targeted expression of a Braf V600E allele in EMPs does not lead to leukaemic/tumoural transformation, in contrast to the targeting of HSC-derived progenitors, and results in otherwise healthy mice carrying clones of resident macrophages with BRAF(V600E) that have a small proliferative advantage.
To determine the potential effects of macrophage clones with BRAF(V600E) in adult tissues, we longitudinally analysed a large cohort (n = 155) of Braf VE mice and littermate controls. We found that Braf VE mice developed slow-progressive neurologic impairment ( Fig. 2a-d , Extended Data Fig. 4 and Supplementary Video 1). Young mice did not present with detectable neurological symptoms, as evaluated by the rotarod test. However, from the age of 4-5 months Braf VE mice presented with axial rolling, a unilateral loss of hindlimb reflexes and a unilateral increase in overlap distance between hind and front paws followed by decreased stride length as measured by footprint assays (score 1) ( Fig. 2a, d and Supplementary Video 2). Braf VE mice later developed hindlimb paresis or loss of hindlimb reflexes (score 2), associated with weight loss. At a more advanced stage, Braf VE mice presented in rapid succession with paralysis of one and subsequently of both hindlimbs (score 3 and 4) and full loss of hindlimb reflexes (Fig. 2a, b and Supplementary Video 3); when this occurred, mice were flagged as moribund by veterinary staff and euthanized. Cumulative incidence of score 1 criteria indicated that around 90% of male and female Braf VE mice presented with neurological disease by 7 months Letter reSeArCH 3 9 of age and around 60% of Braf VE mice had progressed to full paralysis by 9 months of age ( Fig. 2c-f ). To further investigate whether neurologic disease was dependent on constitutively active BRAF, we placed Braf VE and Braf wild-type (Braf WT ) mice on an ad libitum diet containing a BRAF inhibitor (PLX4720, Extended Data Fig. 4 ) at one and three months of age. PLX4720 treatment delayed the onset of the neurological phenotype when initiated early (at one month of age) and mitigated disease progression in both cases. By 9 months of age, 80% of Braf VE mice treated with PLX4720 were alive with an average clinical score of 2 ( Fig. 2d-f ). These results suggest that Braf V600E mosaicism in tissue-resident macrophages causes a late-onset progressive neurological disorder with features of cerebellar ataxia, which are also found in patients with cerebral histiocytoses 9, 11 . We next investigated pathological changes that may underlie neurologic impairment in asymptomatic one-month-old Braf VE mice, and found early signs of microglial and astrocyte activation without signs of neuronal damage, such as the deposit of amyloid precursor protein or neuronal loss (Extended Data Fig. 5 ). However, in approximately six-month-old Braf VE mice, large clusters of amoeboid IBA1 + microglia were present in the cerebrum, preferentially located in the thalamus, brain stem, cerebellum and spinal cord (Fig. 2g , h and Extended Data Fig. 6 ). In these areas we also observed LAMP2 + phagocytic microglia, marked astrogliosis, synaptic and neuronal loss, and deposits of amyloid precursor protein ( Fig. 2g, h) . Luxol fast blue-periodic acid-Schiff (PAS) staining indicated demyelination, which was potentially secondary to axonal damage (Extended Data Fig. 6 ). BRAF inhibition reduced microglia accumulation and astrogliosis, phagocytosis, demyelination, neuronal loss and amyloid precursor protein deposits ( Fig. 2h and Extended Data Fig. 6 ). Therefore, mice presented with neuro degenerative disease that was driven by constitutively active BRAF in microglia.
Immunostaining for CD68, IBA1, YFP and phosphorylated (p)ERK demonstrated that microglial clusters represented the accumulation of EMP-derived (YFP + ) pERK + microglia (Fig. 3a, b and Extended Data Fig. 7 ). Microglial ERK-activation in the brain and spinal cord was confirmed by western blot on whole tissue and by confocal microscopy (Fig. 3c, d ; for gel source data, see Supplementary Fig. 1 ). Immunofluorescence analyses also indicated that pERK + YFP + amoeboid microglia had lost their ramifications ( Fig. 3d ). Flow cytometry analysis confirmed the preferential expansion of YFP + microglia ( Fig. 3e , f). Granulocytes, monocytes and B cells were absent or rare, but CD3 + CD8 + , CD3 + CD4 + and CD3 + Foxp3 + T cells were increased ( Fig. 3f and Extended Data Fig. 7 ; for gating strategy, see Supplementary  Fig. 2 ). BRAF inhibition mitigated the accumulation of YFP + microglia, probably by decreasing their proliferation ( Fig. 3e, g) , and prevented ERK phosphorylation and the amoeboid phenotype of microglia ( Fig. 3b-d ). Together, our data suggest that Braf V600E somatic mosaicism in microglia drives neurodegenerative disease mediated by microglial activation.
We therefore investigated the cellular and molecular mechanisms by which microglia drive neurodegenerative disease. RNA-seq analysis of fluorescence-activated cell-sorted YFP + microglia from paralyzed Braf VE mice and control littermates identified around 8,000 differentially expressed genes, 80% of which were upregulated (Supplementary Table 3 ). Gene set enrichment analysis of differentially expressed genes identified RAS signalling, complement activation and inflammatoryresponse signatures, including expression of IL-1b, IL-18, IL-6 and IL-17, genes associated with phagocytosis such as cathepsins and pattern-recognition receptors, growth factors and growth factor receptors that are usually expressed by fibroblasts, and matrix-associated genes such as laminins and collagens ( Fig. 4a, b ). Expression of Dectin-1 (also known as Clec7a), LFA-1 (also known as CD11a or ITGAL), VLA-4 (also known as CD49d or ITGA4), the PDGF receptor, IL-1b and IL-17a and the decrease in expression after PLX4720 treatment was confirmed at the protein level and collagen IV and VI deposition was observed at sites of YFP + microglia accumulation ( Fig. 4c-f ). These results indicate that the pathological consequences of microglial ERK activation include the accumulation of amoeboid microglia producing inflammatory cytokines of the IL-1/IL-18 and IL-6/IL-17 families, which are mediators of neuronal loss and neurodegeneration [28] [29] [30] and local matrix remodelling, including the production of collagen.
Of note, apart from the hindbrain, midbrain and thalamus, expansion of YFP + F4/80 + pERK + macrophages was also detected in the forebrain and in organs outside of the central nervous system, such as the liver (Extended Data Fig. 8a-c ). However, we did not observe histological or biological signs of liver, spleen, lung or kidney damage in mice housed in specific-pathogen-free conditions in the course of this study (Extended Data Fig. 8d-f ). Possible explanations for the finding that ERK-activated macrophages are better tolerated outside the posterior part of the brain may relate to cell-autonomous or cell-extrinsic homeostatic mechanisms that operate in various anatomical locations and tissue niches, such as the greater exposure to microbial and environmental stimuli in the liver. Results from our model therefore suggested that neurodegenerative diseases in patients with histiocytoses may involve the accumulation of ERK-activated microglia, producing inflammatory cytokines and collagen at sites of neurodegeneration, but there was little prior data evaluating microglia in patients with histiocytoses. We therefore analysed brain tissue from five patients with Erdheim-Chester disease (ECD)-, Langerhans cell histiocytosis (LCH)-and Juvenile Xanthogranuloma (JXG)-associated neurodegenerative disease, who carried a BRAF mutation (ref. 17; Fig. 4g -i, Extended Data Fig. 9 and Supplementary Table 4 ). In patients with ECD, we observed microglial activation, in the form of numerous amoeboid BRAF(V600E) + CD163 + microglia with nuclear pERK + staining at sites of neuronal loss, astrogliosis and demyelination (Fig. 4g, h and Extended Data Fig. 9b, c) . Comparison of the transcriptome from the JXG and LCH brain biopsies with control brain tissue also identified a MAPK-pathway activation signature and indicated increased expression of IL1B, IL18, IL6 and IL17A, pattern-recognition receptors and cathepsins, as well as PDGF receptor and collagen genes ( Fig. 4i ). Therefore, brain tissues from human patients shared key histological, cellular and molecular features observed in the mouse.
In summary, our data indicate that mosaic expression of a Braf V600E allele in the resident macrophage lineage gives rise to clonal expansion of ERK-activated microglia, causing synaptic and neuronal loss that predominates in the hindbrain, midbrain and thalamus, ultimately leading to a lethal neurodegenerative disease in adult mice. Phagocytosis and production of neurotoxic mediators of the IL-1 and IL-17 families may account, at least in part, for the observed neurodegeneration. Loss of microglial ramifications and matrix remodelling may also compromise synaptic connectivity. More generally, the finding that MAPK signalling in microglia causes neurodegeneration in mice supports the idea that pharmacological inhibition of this pathway might represent a useful strategy to prevent neuronal death in neurodegenerative diseases.
Our data also indicate that the pathophysiological consequences of a somatic BRAF(V600E) mutation in different haematopoietic lineages are markedly distinct. BRAF(V600E) expression in HSCs can cause a tumoural disease, but results in a neurodegenerative inflammatory disorder when expressed in EMP, thereby linking the pathophysiology of clonal and neurodegenerative disorders. The clinical heterogeneity of histiocytoses in humans may result in part from mosaicism in distinct lineages. Beyond patients with histiocytoses, somatic mutations, including BRAF(V600E), spontaneously arise in normal and tumoural tissues 24, 25 , suggesting the intriguing possibility that somatic mutations in microglia could contribute to the pathogenesis of commonly encountered forms of neurodegenerative diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Targeting of BRAF(V600E) mutation to EMPs and EMP-derived cells.
EMPs appear in the yolk sac at embryonic day (E)8.5 and express the Csf1 receptor (Csf1r) 20, 22, 23 . They colonize the fetal liver from E9.5 and give rise to macrophage precursors that distribute in embryonic tissues and differentiate into tissue-specific macrophage subsets, such as microglia in the central nervous system 23 . Therefore, to investigate the consequences of Braf V600E expression in the EMP lineage, we genetically targeted EMPs by pulse-labelling Csf1r MeriCreMer ;Braf LSL-V600E ;Rosa26 LSL-YFP E8.5 embryos with 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich) 20 20, 22, 27, 31 and Braf LSL-V600E mice 26 (provided by C. Pritchard (Leicester, UK)) were maintained under specificpathogen-free conditions. Animal procedures were performed in adherence to our project licenses issued by the UK Home Office under the Animals (Scientific Procedures) Act 1986 and Institutional Review Board (IACUC 15-04-006 and 13-04-003) from MSKCC. Genotyping was performed according to protocols described previously for Csf1r iCre (ref. 32 cre + mice were considered Braf WT for representation of data. For BRAF inhibition, mice were placed on an ad libitum PLX4720 diet at one or three months of age (PLX4720containing chow 417 p.p.m., provided by Plexxikon Inc 33 ). Braf WT and Braf VE male and female littermates were assigned randomly into the control or treated group. Scoring of mice was performed blinded and at least weekly by assessing hindlimb reflexes and other behavioural phenotypes such as axial rolling 34, 35 . The investigators were not blinded to allocation during experiments and outcome assessment. Footprint analysis. Mice were given two trials to run down a runway before the experiment. Mouse forepaws and hindpaws were painted with red and blue ink, respectively. Mice were then allowed to run down a runway lined with white paper. At least four steps from the middle portion of each run were measured for (1) overlap between forepaw and hindpaw placement; (2) stride length; (3) front-base width (the distance between the right and left forelimb strides); and (4) hind-base width (the distance between the right and left hindlimb strides) 36 . Mean values were used for graphs and statistical analyses. Rotarod assay. The assay was conducted using a ROTO-ROD series 8 (IITC life sciences) with accelerating speed (accelerated from 4 to 40 r.p.m. over 120 s). The mice were trained on the accelerating rotarod with three training session per day for three days. On the day of the experiment, the mean latency to fall off the rotarod recorded in the three trials was used for analysis. Preparation of cell suspensions, flow cytometry and cell sorting. Pregnant females were killed by exposure to CO 2 . Embryos were removed from the uterus, washed in 4 °C phosphate-buffered saline (PBS, Invitrogen) and dissected under a Leica M80 microscope. For blood phenotyping of adult mice, mice were anaesthetized and blood was collected by cardiac puncture. Bone marrow was collected by flushing one leg with 5 ml RPMI (Invitrogen). For flow cytometry experiments, organs were incubated in PBS containing 1 mg ml −1 collagenase D (Roche), 100 U ml −1 DNase I (Sigma-Aldrich), 2.4 mg ml −1 of dispase (Invitrogen) and 3% FCS (Invitrogen) at 37 °C for 30 min before mechanical disruption. For embryonic tissue, the incubation time at 37 °C was reduced to 20 min. For cell sorting, tissues were digested for 30 min at room temperature in PBS containing 2 mg ml −1 of collagenase D (Roche), 200 U ml −1 DNase I (Sigma-Aldrich), 4.8 mg ml −1 of dispase (Invitrogen), 3% FCS (Invitrogen) and 1 μM of flavopiridol (Sigma-Aldrich) followed by mechanical disruption under a 100-μm filter. Cell suspensions were centrifuged at 320 g for 7 min, resuspended in FACS buffer (PBS, 0.5% BSA and 2 mm EDTA) containing purified anti-CD16/32 (1:100 dilution) and 5% normal mouse, 5% normal rat and 5% normal rabbit serum and incubated for 15 min at 4 °C. Samples were immunostained with antibody mixes for 30 min at 4 °C. For FMO (fluorescence minus one), brain cell suspensions from Braf WT and Braf VE mice were mixed before staining. The full list of antibodies used can be found in Supplementary Table 5 . Cell sorting was performed using an Aria III BD cell sorter. Single live cells were gated on the basis of dead cell exclusion (DAPI), side (SSC-A) and forward scatter (FSC-A) gating, and doublet exclusion using forward scatter width (FSC-W) against FSC-A. Macrophage populations were identified after gating on CD45 based on expression of F4/80, CD11b and YFP. For each sample, 200 cells were directly sorted into a 96-well plate (Biorad) in 4 μl of H 2 O containing 0.2% of Triton X-100 (Sigma-Aldrich) and 0.8 U μl −1 of RNase inhibitor (Clontech), and processed as indicated below.
For intracellular stainings, cell suspensions were purified by a Percoll (Sigma-Aldrich) gradient (70/37/30%), and cells were collected from the 70/37 interface. After washing twice with PBS, cells were stained with a viability dye (Ghost Dye Red 780, Tonbo Biosciences) according to the manufacturer's protocol. Cells were first stained with antibodies for surface markers (see Supplementary Table 5 ), then processed for intracellular staining using the Foxp3/Transcription Factor Staining Buffer Set (Affymetrix eBioscience) according to the manufacturer's protocol. Cell numbers per organ or per gram of tissue were calculated as follows. For embryonic tissues, cell suspensions were prepared, stained and acquired from whole organs, and the number of live cells per tissue was directly obtained from FCS files. In adult mice, organs were weighted, cell suspensions were prepared from 20 to 500 mg of tissue, and the number of cells per gram of tissue was determined using a cell counter (GUAVA easyCyte HT). For gating strategies used for different tissues, see Supplementary Fig. 2 . Proportion of YFP + F4/80 + cells in tissues from Braf VE and Braf WT littermates were analysed by calculating the proportion of YFP + cells among F4/80 + cells. Values from Braf WT littermates were then normalized and set to one. Generation and analysis of Kupffer cells and microglia RNA-seq in Braf VE mice and Braf WT littermate controls. Sorted cells underwent amplification (14 cycles) using the SMART-seq V4 (Clonetech) ultra-low input RNA kit for sequencing. Illumina hiseq libraries were prepared using 10 ng of amplified cDNA and the Kapa DNA library preparation chemistry (Kapa Biosystems) using 8 cycles of PCR. Samples were barcoded and run on a Hiseq 2500 1T in a 50 bp-50 bp paired-end run, using the TruSeq SBS Kit v.3 (Illumina). An average of 54 million paired reads was generated per sample and the percentage of mRNA bases was almost 77% on average. FASTQ files were mapped to the mouse genome mm10 using the Star aligner 37 that maps reads genomically and resolves reads across splice junctions. We used several QC metrics for the RNA-seq library, including intron-exon ratio, intragenic reads fraction and GC bias. We quantified exon and gene expression using Sailfish against the Mus musculus transcriptome GRCh38 (ref. 38) . After merging technical replicates, differential expression tests were performed using the DESEQ2 algorithm 39 . We considered genes that had a FDR < 0.01 to be significantly different between genotypes and ranked significant genes by fold change with a cutoff of one. Gene set enrichment analysis on KEGG pathway, GO term, Reactome and MSigDB gene set collection was done using the over-representation test with a hypergeometric model to assess whether the number of selected genes associated with disease is larger than expected 40 . Generation and analysis of RNA-seq of human brains. Snap-frozen brain tissues of normal subjects were obtained from the MSKCC Medical Donation Program. RNA was extracted using the Qiagen all-prep DNA/RNA mini kit (80204) according to the manufacturer's instructions. RNAs were used for ribogreen quantification and quality control on Agilent BioAnalyzer. Average amount was 5.3 μg, Average RIN was 8.9. Subsequently, 500 ng of total RNA was used for polyA selection and Truseq library preparation according to the instructions provided by Illumina (TruSeq RNA Sample Prep Kit v.2), with 8 cycles of PCR. Samples were barcoded and run on a Hiseq 4000 in a 125 bp-125 bp paired-end run, using the TruSeq SBS Kit v.3 (Illumina). An average of 75 million paired reads was generated per sample. At the most, the ribosomal reads represented 7% and the percentage of mRNA bases was close to 45% on average. FASTQ files from brain samples of controls and previously sequenced brain samples of patients with JXG and LCH (SJLCH13 and SJLCH14) 17 were mapped to the human genome GRCh37 using Star aligner. We used several QC metrics for the RNA-seq library, including intron-exon ratio, intragenic reads fraction and GC bias. We quantified exon and gene expression using Salmon against the Homo sapiens transcriptome GRCh37 38 . Differential expression tests, statistical tests and pathway analysis was performed as described above for mouse RNA-seq. Immunofluorescence, imaging and analysis (mouse). Embryos were imaged using a Leica M80 or Zeiss Axio Zoom.V16. Tissues were fixed for 1-3 days in 4% formaldehyde (Sigma-Aldrich). After fixation, tissues for cryosections were incubated overnight in 30% sucrose and embedded in OCT compound (Sakura Finetek). Cryoblocks were cut at a thickness of 16 μm for liver and 50 μm for spinal cord and brain, and then blocked with PBS containing 10% normal goat serum (Invitrogen), 1% BSA (w/v) and 0.3% Triton X-100 for 1 h at room temperature. Livers were incubated overnight, brains and spinal cord for 48 h at 4 °C with rat anti-mouse F4/80 (1:300, MCA497GA, Biorad), rabbit anti-mouse IBA1 (1:300; 019-19741, Wako), chicken anti-GFP (1:500, A10262, Invitrogen, crossreactive to YFP), rabbit anti-pHis3 (1:100, sc-8656-R, Santa Cruz), goat anti-IL-1b (1:40, AF-401-SP, R&D), rabbit anti-pERK1/2 (1:100, 4370, Cell signaling), rabbit anti-collagen IV (1:100, 2150-1470, Biorad) , rabbit anti-collagen VI (1:200, ab6588, Abcam), rabbit anti-cleaved caspase-3 (1:600, 9661, Cell Signaling),
Letter reSeArCH
rat anti-Ki-67 (1:200, 14-5698-80, eBioscience). Secondary anti bodies used were anti-rabbit Cy3 (1:500, Invitrogen), anti-chicken Alexa Fluor 488 (1:500, Invitrogen), anti-rat Alexa Fluor 647 (1:500, Invitrogen), anti-goat Alexa Fluor 568. Samples were then mounted with Fluoromount mounting medium with DAPI (eBiosciences) and visualized using a LSM880 Zeiss microscope with 20×/0.5 (dry) and 40×/1.4 (oil) performing a tile scan and z stack on whole tissue at a 512 × 512 or 1,024 × 1,024 pixel resolution. Image analysis and cell quantification was performed using Imaris (Bitplane) software. For paraffin sections, 3-μm sections were prepared before staining with H&E, Trichrome and luxol fast blue (LFB-PAS). Primary antibodies were rabbit anti-CD68 (5 μg ml −1 , PA1518, Boster Biological Technology), rabbit anti-pERK1/2 (1 μg ml −1 , 4370, Cell signaling), chicken anti-GFP for YFP detection (1:5,000, ab13970, Abcam), mouse anti-APP (1:3,000, MAB348, Millipore), rabbit anti-IBA1 (1:500, 019-19741, Wako), rabbit anti-GFAP (1:200, Z0334, Dako) , mouse anti-NeuN (1:200, MAB377, Merck Millipore), rat anti-LAMP2 (1:250, ab13524, Abcam), mouse anti-pERK1/2 (1:200, sc-136521, Santa Cruz), rabbit anti-homer1 (1:200, 160003, Synaptic Systems), mouse anti-synaptophysin (1:500, 101 011, Synaptic Systems). Primary antibodies were incubated overnight at 4 °C. Secondary Alexa-or HRP-conjugated antibodies were added at 1:200 in antibody buffer for 2 h at room temperature. For immunofluorescent staining, nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, 236276, Boehringer). All slides were mounted in Vectashield (Vector Laboratories). Images were taken using a Zeiss Laboratory.A1 or BZ-9000 Biorevo microscope (Keyence) and analysed using the BZ-II Analyzer (Keyence). For quantification of cell numbers, at least three parasagittal sections per mouse were analysed. In cases where the cell density was too high and single cells could not be quantified, we quantified the immunolabelled area size per brain section. To determine synapse density, imaging was performed using an Olympus Fluoview 1000 confocal laser scanning microscope using a 20×/0.95 NA objective. z stacks with 0.05-μm steps in the z direction, 1,024 × 1,024 pixel resolution, were recorded and analysed using Imaris software (Bitplane). Colocalization of the presynaptic marker synaptophysin with the postsynaptic marker homer1 was quantified. Immunofluorescence, imaging and analysis (human). Written informed consent was obtained from patients with histiocytosis for DNA/RNA sequencing and immunohistochemical studies according to the Helsinki convention, and this study received approval from the Institutional Review Board at MSKCC (IRB Protocol 06-107). For all patients with ECD, ECD was diagnosed in light of published guidelines for the diagnosis and clinical management of ECD 41 . Biopsy material was retrieved from the pathology archives at the Memorial Sloan Kettering Cancer Center. Immunohistochemistry of human tissue of patients with ECD and controls (see Supplementary Table 6 ) was carried out on 3-4-μm thick paraffin sections, fixed with PFA. Immunohistochemical analysis was performed on paraffin sections with rabbit anti-IBA1 (1:500, 019-19741, Wako) and mouse anti-pERK1/2 (1:200, sc-136521, Santa Cruz) or mouse anti-CD163 (0.06 μg ml −1 , 760-4437, Cell Marque), rabbit anti-pERK1/2 (1 μg ml −1 , 4370, Cell Signaling) and mouse anti-BRAF(V600E) (VE1) (1:800, E19294, clone VE1, Spring). Secondary Alexa-or HRP-conjugated antibodies (Invitrogen) were added at 1:200. Images were taken with a Zeiss Laboratory.A1, BondIII (Leica-Microsystems), BZ-9000 BIOREVO microscope (Keyence) and analysed using the BZ-II Analyzer (Keyence) or with a LSM880 Zeiss microscope with 40×/1.4 (oil), performing a tile scan and z stack on the whole tissue at a 512 × 512 or 1,024 × 1,024 pixel resolution and manually analysed using Imaris (Bitplane) software. Western blot. Tissues were homogenized using a cell lysis kit (Biorad) and a Precellys homogenizer. Primary antibodies were added overnight at a dilution 1:1,000 for rabbit anti-pERK1/2 (4370, Cell Signaling) and rabbit anti-ERK1/2 (9102, Cell Signaling) and 1:5,000 mouse anti-β-actin (ab6276, abcam). Secondary antibodies, anti-rabbit HRP (7074, Cell Signaling) or anti-mouse AP (AP-2000, Vector laboratories), were added for 1 h at a dilution of 1:2,000. Detection of HRP was performed using Pierce ECL Western Blotting substrate (32106). Detection of AP was performed using a BCIP/NBT substrate kit (SK-5400, Vector laboratories). For quantification, a ratio was made of the total integrated optical density of pERK bands to the integrated optical density of bands of the corresponding total ERK protein using ImageJ. Cytokine analysis in spinal cords. Proteins were extracted from 25 mg of tissue using Bio-Plex cell lysis kit. Cytokine concentrations were measured using Bio-Plex Pro Mouse Cytokine 23-plex Assay according to the manufacturer's protocol. Serum analysis. 70-75 μl of serum was analysed for liver enzymes using a Beckman Coulter AU680 Chemistry analyser. PLX4720 concentration measurements. Analysis of PLX4720 concentrations in brain, liver and serum was performed in collaboration with Plexxikon Inc. 25 μl serum and 20 mg of homogenized tissue were measured using a standard curve that was generated by adding known amounts of PLX4720 to an untreated serum or homogenized sample. Statistical analysis and reproducibility. Data are shown as mean with individual values per mouse represented as circles, unless stated otherwise. Statistical significance was analysed with GraphPad Prism using Mann-Whitney U-tests, unpaired two-tailed t-tests, one-way and two-way ANOVA and log-rank (Mantel-Cox) test as indicated in the figure legends. The n value represents biological replicates. For RNA-seq statistical analysis R software was used (see 'Generation and analysis of Kupffer cells and microglia of RNA-seq in Braf VE mice and Braf WT littermate controls' and 'Generation and analysis of RNA-seq of human brains'). Significance was considered at P < 0.05. Animals that were labelled moribund by veterinarian services had to be euthanized and were therefore excluded from further longitudinal analyses as indicated in the figure legends. Kaplan-Meier survival analysis was used to estimate overall survival and cumulative incidence rate. Experiments were repeated to ensure reproducibility of the observations. Equal variance was assumed for cell-counting experiments. No statistical methods were used to predetermine sample size. Data availability. Gene expression data are deposited in the GEO database (accession number GSE95734). The data that support the findings of this study are available from the corresponding author upon reasonable request. Braf VE mice (n = 5-6) and Braf WT mice (n = 6) on control diet, and 7-9-month-old Braf VE mice (n = 6) and Braf WT mice (n = 4) on PLX4720 diet. Circles represent values for individual mice. One-way ANOVA. *P < 0.05, **P < 0.01. e, CD3 immunohistochemistry of brain and spinal cord of 6-month-old Braf VE and Braf WT mice. Anatomical regions of insets are indicated. Representative of n = 5 Braf WT and n = 4 Braf VE mice. Scale bars, 500 μm (spinal cords), 1 mm (brains) and 50 μm (insets). f, g, Analysis of CD8 + , CD4 + and Foxp3 + T-cell numbers (f) and proliferation (g) in brain and spinal cord by flow cytometry in 5-8-month-old Braf VE (n = 4) and Braf WT (n = 6) mice on control diet, and 7-9-month-old Braf VE (n = 6) and Braf WT (n = 5) mice on PLX diet. Circles represent values for individual mice. One-way ANOVA.
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample size. To study the consequences of BRAFV600E on the behavior a cohort of mice (n=10 per group) was studied and initial analysis was performed using Log-rank and 2-way ANOVA statistical analyses. Results from these experiments indicated that the phenotype was robust (100% genotype to phenotype penetrance) and subsequent experiments were done with a sample size of 4-7 mice per group.
Data exclusions
Describe any data exclusions. No data was excluded
Replication
Describe whether the experimental findings were reliably reproduced. All attempts for replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
BRAFWT and BRAFVE male and female littermates were assigned randomly into the control or treated group.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Initial scoring (score 1) of mice was performed blinded. The investigators were not blinded to allocation during following experiments and outcome assessment.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
